1Cutlip DE, Windeeker S, Mehran R, et al. Clinical end points in cormary stent trials: a case for standardized definitions. Circulation, 2007, 115: 2344-2351.
2Peter W, Christoph R, Franz R, et al. Clinical research Stent thrombosis fnllowing hare-metal stent implantation: success of emergency pereutaneous coronary intervention and predictors of adverse outcome. European Heart Journal, 2005, 26:1180-1187.
3Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-chJting steut thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coil Cardiol, 2008.52: 1134-1140.
4Fujii K, Carlier SG, Mintz GS, et zl. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coil Cardiol, 2005, 45: 995-998.
5Biondi-Zoceai GG, Agostoni P, Sangiorgi GM, et al. Incidence, predictors, and outcomes of coronary dissections left untreated after drng-eluting stent implantation. Eur Heart J, 2006, 27: 540-546.
6Joner M, Finn AV, Farb A, et al. Pathology of drug-elnting stenls in humans: delayed healing and late thrombotic risk. J Am Coil Cardiol, 2006, 48: 193-202.
7R/iber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus- eluting and paclitaxel-eluting stems: results of the sirolimus-eluting versus paclitaxel-eluting stems for coronary revascularization LATE trial. Circulation, 2011, 123:2819-2828,.
8Cook S, Wenaweser P, Togni M, et ah Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation, 2007, 115: 2426-2434.
9Ako J, Morino Y, Honda Y, el al. Late incomplete stem apposition after sirolimus-eluting stent implantation: a serial intravaseular uhrasound analysis. J Am Coll Cardiol, 2005, 46: 1002-1005.
10van Werkum JW, Heestermans AA, Zomcr AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thr>mb>sis Begistry. J Am Coil Cardinal, 2009, 53: 1399-1409.
二级参考文献7
1Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),European Association for Percutaneous Cardiovascular Interventions (EAPCI),Wijns W. Guidelines on myocardial revascularization[J].European Heart Journal,2010.2501-2555.
2Levine GN,Bates ER,Blankenship JC. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions[J].Circulation,2011.e574-e651.
3Hillis LD,Smith PK,Anderson JL. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery.A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.developed in collaboration with the American Association for Thoracic Surgery,Society of Cardiovascular Anesthesiologists,and Society of Thoracic Surgeons[J].Journal of the American College of Cardiology,2011.e123-e210.
4Nashef SA,Roques F,Michel P. European system for cardiac operative risk evaluation (EuroSCORE)[J].European Journal of Cardio-Thoracic Surgery,1999.9-13.
5Serruys PW,Morice MC,Kappetein AP. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J].New England Journal of Medicine,2009.961-972.
6Peterson ED,Dai D,DeLong ER. Contemporary mortality risk prediction for percutaneous coronary intervention:results from 588,398 procedures in the Natio Cardiovascular Data Registry[J].Journal of the American College of Cardiology,2010.1923-1932.
